Quick Answer: A 2026 Nature Metabolism study gave retatrutide and cagrilintide together to diet-induced obese male rats. The pair lowered body weight more than either compound alone and more than matched semaglutide or tirzepatide pairings. The study did not test humans, females, long-term safety or any premixed blend.
Key Takeaways
- One primary retatrutide cagrilintide combination study exists as of October 2026, per our PubMed review. It was run in rats.
- The rats were male and diet-induced obese. Each received daily co-administration of the two compounds.
- Pair-feeding and weight-matching experiments suggest the extra weight loss was not explained by eating less alone.
- No human trial of the pair appears in the study. Human data exist only for each compound on its own, or for cagrilintide with semaglutide (CagriSema).
- Neither retatrutide nor cagrilintide had FDA approval when this page was written. Both remain investigational.
- A rat result is a reason to run a human trial. It is not evidence that a human effect exists.
Research Use Only. All compounds discussed on this page are sold by 99 Purity Peptides strictly for laboratory research. They are not for human or veterinary consumption. Nothing on this page is medical advice, dosing guidance or a health claim. We summarise the studies here for research context only.
Online vendors now market retatrutide cagrilintide pairings as if their combined effect were settled. It is not. In fact, the published evidence for the pair comes from a single animal study. That study appeared in Nature Metabolism on 15 September 2026, and it is a careful piece of work. Still, careful rat data and human proof are different things.
This page reads the primary paper in plain language. It also sets out what the human record shows for each compound separately. Finally, it explains what evidence researchers would need before anyone could call the combined effect established.
What Did the Rat Study Actually Test?
The paper is titled "Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats." According to PubMed, Petersen, Merrild and colleagues at the University of Copenhagen published it on 15 September 2026 [1].
The authors describe retatrutide as a "unimolecular GLP-1R/GIPR/GCGR tri-agonist." In other words, one molecule acts on three receptors. Meanwhile, they describe cagrilintide as an amylin and calcitonin receptor co-agonist (AMLNR/CALCR). Together, the pair engages five receptor types.
The study design in brief
The abstract lists four main components:
- Dose-response work. Diet-induced obese male rats received both compounds daily. Weight and food intake fell in a dose-dependent way.
- Comparator arms. The authors compared the pair with each compound alone at an equimolar dose. They also compared it with matched-dose pairings of cagrilintide with semaglutide or tirzepatide.
- Control experiments. Pair-feeding and weight-matching groups helped separate drug effects from simple calorie reduction.
- Molecular profiling. The team ran plasma proteomics and gene-expression profiling in two brain regions: the hypothalamus and the dorsal vagal complex.
The published figure legends add useful detail. For example, one high-dose study ran 13 days of daily injections, with 8 to 10 rats per group. Separately, a taste-aversion test used lean, chow-fed Sprague-Dawley rats. These are short studies, which is typical for preclinical pharmacology.
What the abstract reports
Per the abstract, the combination reduced body weight and food intake more than either monotherapy. It also beat the semaglutide and tirzepatide comparator pairings at matched doses. In addition, it improved circulating cholesterol, triglycerides and insulin.
Notably, the abstract never uses the word "synergy." It says the pair exceeded the single compounds. That is a different claim. We could not access the full text to check whether a formal additivity test was run. Therefore, this page does not describe the result as synergistic.
Who ran the study, and disclosures
The authors work at the Novo Nordisk Foundation Center for Basic Metabolic Research. The paper describes this centre as an independent research unit at the University of Copenhagen. The Novo Nordisk Foundation partly funds it.
The paper's competing-interests statement is worth reading. Several authors co-founded obesity and cardiometabolic biotech companies. One author has received speaking fees from Novo Nordisk. Another has received research support from Novo Nordisk and counselling fees from Eli Lilly and Zealand Pharma. These disclosures do not invalidate the work. However, they belong in any honest summary.
Why Do Pair-Feeding and Weight-Matching Matter?
First, consider that most obesity drugs reduce appetite. So when a treated animal loses weight, the obvious question is simple. Did the drug do anything beyond making the animal eat less?
Pair-feeding answers that question. Untreated control rats receive exactly the amount of food the treated rats chose to eat. If the treated rats still lose more weight, then intake alone cannot explain the gap. According to the abstract, that is what the authors found for the combination.
Weight-matching works differently. Here, a control group is food-restricted until it loses the same weight as the treated group. Consequently, researchers can compare two groups of equal weight loss. Any molecular difference left over is more likely to be a drug effect, not a weight-loss effect.
Without these controls, a striking weight curve says little about mechanism. With them, the rat data become far more interpretable. Even so, they remain rat data.
What the rat study measured versus what a human claim would need
Question | What the rat study provides | What a human claim would require |
|---|---|---|
Does the pair lower body weight? | Yes, in male diet-induced obese rats over short studies | Randomized, placebo-controlled human trial with the pair as a treatment arm |
Is the effect more than either compound alone? | Yes, versus equimolar monotherapy in rats | Factorial human trial: pair vs each compound vs placebo |
Is the effect beyond reduced eating? | Pair-feeding suggests yes, in rats | Human energy-expenditure and body-composition studies |
Is it safe? | Short-term rat markers only | Long-term human safety data, including GI tolerability and discontinuation |
Does it work in females? | Not tested (male rats only) | Human trials enrolling both sexes |
What dose ratio works? | Rat doses in nmol/kg | Human dose-finding studies |
Does a premixed blend behave the same? | Not described; the abstract reports co-administration | Formulation stability and human pharmacokinetic studies |
Did the Study Include Human Data?
No. In short, the title, abstract and figure legends describe rat experiments only. The in vitro receptor work used cell lines expressing human, rat and mouse receptors. Cell assays, however, are not human trials.
This matters because rats and people differ in drug exposure, metabolism and dosing intervals. For instance, the rats received daily doses. By contrast, human trials of each compound have used once-weekly injections. A dose that works in a rat does not translate directly to a person.
What Does the Human Record Show for Each Compound?
By contrast with the pair, each compound has a substantial human trial record. Neither record, though, includes the other compound. The table below separates what exists from what does not.
Evidence types: what exists, and where
Evidence type | Retatrutide + cagrilintide (pair) | Retatrutide (alone) | Cagrilintide (alone or with semaglutide) |
|---|---|---|---|
Rodent combination study | Yes — one paper (Petersen et al., 2026, male rats) | Not applicable | Not applicable |
Human randomized trial of the pair | None identified | Not applicable | Not applicable |
Phase 2 human trial | None identified | Yes — 48 weeks, 338 adults with obesity (NCT04881760) | Yes — cagrilintide alone, 26 weeks, adults with overweight or obesity (NCT03856047) |
Phase 3 human trials | None identified | Yes — TRANSCEND-T2D-1 (published); TRIUMPH-2 and TRIUMPH-3 (topline results) | Yes — as CagriSema, e.g. REDEFINE 1 (published) |
Systematic review or network meta-analysis | None | Yes — BMJ Medicine 2026; Annals of Internal Medicine 2026 | Yes, as CagriSema — BMJ Medicine 2026 |
FDA marketing approval | No | No (application planned for Q1 2027) | No (CagriSema application under FDA review) |
Retatrutide on its own
According to PubMed, the phase 2 trial by Jastreboff and colleagues enrolled 338 adults with obesity, or overweight plus a weight-related condition [4]. At 48 weeks, the 12 mg group lost 24.2% of body weight on average. The placebo group lost 2.1%.
Phase 3 data have since followed. In TRANSCEND-T2D-1, adults with type 2 diabetes received retatrutide or placebo for 40 weeks [5]. Body weight fell 15.3% with 12 mg, versus 2.6% with placebo, using the treatment-regimen estimand.
Eli Lilly also reported topline results for TRIUMPH-2 and TRIUMPH-3 on 23 July 2026. These are company announcements, not yet peer-reviewed papers. In TRIUMPH-2, adults with type 2 diabetes and obesity or overweight lost 20.8% at 80 weeks on 12 mg, versus 4.0% on placebo. In TRIUMPH-3, adults with severe obesity and cardiovascular disease lost 22.6% on 12 mg, versus 3.2% on placebo. Both figures use Lilly's efficacy estimand.
Cagrilintide on its own and with semaglutide
According to PubMed, a phase 2 trial by Lau and colleagues tested once-weekly cagrilintide alone for 26 weeks [6]. Weight fell 6.0% to 10.8% across doses, compared with 3.0% on placebo. That figure uses the trial product estimand.
Most later work pairs cagrilintide with semaglutide as CagriSema. In REDEFINE 1, adults without diabetes received CagriSema or placebo for 68 weeks [7]. Weight fell 20.4% with CagriSema versus 3.0% with placebo. The trial also included a cagrilintide-alone arm.
What the two 2026 evidence syntheses report
In addition, two reviews pooled the human trials in 2026. Each reports retatrutide separately. Neither contains any retatrutide-plus-cagrilintide data.
BMJ Medicine network meta-analysis. According to PubMed, Chen and colleagues analysed 58 trials with 24,214 adults with overweight or obesity and without diabetes [2]. Compared with placebo, retatrutide produced −22.10% weight change (95% CI −25.60% to −18.60%). CagriSema produced −17.32% (95% CI −19.32% to −15.32%). The authors also noted low-certainty evidence of higher discontinuation with retatrutide.
Annals of Internal Medicine updated review. According to PubMed, Moiz and colleagues reviewed 38 trials with 25,816 adults without diabetes [3]. Placebo-subtracted weight loss with retatrutide was −22.1% (95% CI −24.9% to −19.3%). Head-to-head data showed greater weight loss with CagriSema than with semaglutide.
These figures come from different study populations and methods. Therefore, readers should not add them together or use them to estimate what the pair would do in people.
Why Do Researchers Pair Retatrutide With Cagrilintide?
Put simply, the logic is receptor coverage. Retatrutide already acts on three incretin-family receptors. Cagrilintide adds a fourth pathway: amylin signalling through amylin and calcitonin receptors. The rat paper calls this approach five-receptor polypharmacology.
Precedent also exists. CagriSema showed that adding cagrilintide to a GLP-1 agonist can add weight loss in humans. The rat study asks whether the same holds for a stronger partner. In fact, the authors frame their findings as guidance for designing future single molecules that hit all five receptors.
For background on the amylin pathway, see our guide to amylin, IAPP and cagrilintide. For a receptor-level comparison, see how retatrutide's mechanism differs from tirzepatide and semaglutide. In addition, our cagrilintide vs semaglutide comparison covers the two halves of CagriSema.
Is the Retatrutide Cagrilintide Pair Approved?
No. Neither compound, alone or together, had FDA marketing approval when this page was written.
Retatrutide. Lilly's 23 July 2026 release calls retatrutide investigational [8]. It also states that Lilly plans to file with the FDA in the first quarter of 2027.
Cagrilintide. Novo Nordisk filed a New Drug Application for CagriSema on 18 December 2025 [9]. Reporting from 21 September 2026 indicates that an FDA decision is expected in the fourth quarter of 2026. We found no FDA approval of CagriSema or of cagrilintide alone as of that date.
FDA position. The FDA's page on unapproved GLP-1 drugs was current as of 1 October 2026 [10]. It states that retatrutide and cagrilintide cannot be used in compounding under federal law. It also says neither is a component of an FDA-approved drug or has been found safe and effective for any condition.
What Would Have to Be True Before the Combined Effect Is Established?
The rat paper is a hypothesis generator. As a result, researchers would need several further steps before anyone could call the combined effect established:
- Replication. An independent group would need to reproduce the rat findings, ideally in both sexes.
- Longer animal studies. Chronic dosing would show whether the effect persists and whether new safety signals appear.
- Human pharmacology. Phase 1 studies would need to check whether the two compounds alter each other's exposure.
- Human dose-finding. A phase 2 trial would need to identify a dose ratio, with tolerability as a key outcome.
- A factorial human trial. The pair would need to beat each compound alone, and placebo, in a randomized design.
- Long-term safety data. Large human studies would also need to track gastrointestinal effects and discontinuation rates.
As of October 2026, step one onward remains open. Our PubMed review found no human study at any of these stages.
How We Reviewed the Evidence
On 5 October 2026, we searched PubMed for "retatrutide cagrilintide." The search returned 22 records. We then read the title and abstract of each one.
Only one record described an actual combination experiment: the Nature Metabolism rat study. The remaining 21 records were reviews, meta-analyses or commentaries. They mention both compounds, usually in separate sections. Several discuss CagriSema, which pairs cagrilintide with semaglutide, not retatrutide.
Next, we also checked company releases from Eli Lilly and Novo Nordisk, and the FDA's statement on unapproved GLP-1 drugs. We did not cite vendor pages as evidence.
What This Page Does Not Establish
This page does not show that retatrutide and cagrilintide work together in people. It does not establish synergy, since the source abstract does not claim it. Equally, it does not establish safety, a dose ratio or a dosing schedule for any species.
This page also does not show that any premixed product matches the study conditions. The rat study described co-administration, not a commercial blend. Finally, nothing here supports human or veterinary use of either compound.
Separately, preclinical cancer research on retatrutide is a different question with its own evidence base. Our page on retatrutide preclinical cancer studies covers that topic. Readers should keep it apart from the metabolic findings above.
Reading the Retatrutide and Cagrilintide Evidence in Context
The retatrutide and cagrilintide pairing is a legitimate research question. A well-controlled rat study now supports investigating it further. However, the evidence stops there. Each compound has a strong human record on its own, and the pair has none.
For laboratories studying multi-receptor metabolic signalling, the two compounds act on distinct receptor families. Our overview of the 2026 GLP-1 peptide pipeline places both compounds alongside CagriSema and other next-generation agents. As always, every compound we supply is for research use only.
References
- Petersen J, Merrild C, Holm SK, et al. Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats. Nat Metab. 2026. PMID 42744908. https://doi.org/10.1038/s42255-026-01603-y
- Chen D, Ma B, Sun H, et al. Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis. BMJ Med. 2026;5(1):e003026. PMID 42688617. https://doi.org/10.1136/bmjmed-2026-003026
- Moiz A, Filion KB, Samuels AE, et al. Efficacy and Safety of GLP-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes: An Updated Systematic Review. Ann Intern Med. 2026. PMID 42673585. https://doi.org/10.7326/ANNALS-25-05519
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID 37366315. https://doi.org/10.1056/NEJMoa2301972
- Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide in people with type 2 diabetes (TRANSCEND-T2D-1). Lancet. 2026;407(10546):2402-2413. PMID 42250575. https://doi.org/10.1016/S0140-6736(26)00967-0
- Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a phase 2 trial. Lancet. 2021;398(10317):2160-2172. PMID 34798060. https://doi.org/10.1016/S0140-6736(21)01751-7
- Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025;393(7):635-647. PMID 40544433. https://doi.org/10.1056/NEJMoa2502081
- Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials. 23 July 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
- Novo Nordisk. Novo Nordisk files for FDA approval of CagriSema. 18 December 2025. https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916470
- U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of 1 October 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- ClinicalTrials.gov registrations cited: NCT04881760, NCT03856047, NCT05567796, NCT05929079, NCT05882045, NCT06354660.
PubMed-derived bibliographic data and abstracts were retrieved from PubMed (pubmed.ncbi.nlm.nih.gov) on 5 October 2026.
Frequently Asked Questions
What are retatrutide and cagrilintide?
Retatrutide is an investigational single molecule that activates GLP-1, GIP and glucagon receptors. Cagrilintide is an investigational long-acting amylin analogue designed for once-weekly dosing in human trials. Eli Lilly develops retatrutide, while Novo Nordisk develops cagrilintide. Neither had FDA approval as of October 2026, and both are sold here for research use only.
Have retatrutide and cagrilintide been studied together?
Yes, but only in rats. One primary study, published in Nature Metabolism in September 2026, gave both compounds to diet-induced obese male rats. Our PubMed review on 5 October 2026 found no other combination experiment. No human trial of the pair appears in the published literature we reviewed.
What did the 2026 Nature Metabolism study test?
It tested daily co-administration of retatrutide and cagrilintide in obese male rats. The pair was compared with each compound alone and with semaglutide or tirzepatide pairings. The team also ran pair-feeding and weight-matching controls, plasma proteomics and brain gene-expression profiling. All experiments were preclinical.
Was the study done in humans?
No. Every efficacy experiment in the paper used rats, and all treated animals were male. Some receptor assays used cells expressing human receptors, but cell work is not a human trial. Human efficacy and safety for the pair therefore remain untested in the published literature.
Why do researchers pair a GLP-1/GIP/glucagon agonist with an amylin analogue?
The aim is broader receptor coverage. Retatrutide acts on three incretin-family receptors, and cagrilintide adds amylin signalling through a separate receptor family. CagriSema already showed that adding cagrilintide to a GLP-1 agonist can increase weight loss in humans. The rat study asks whether a stronger partner adds more.
Is retatrutide FDA-approved?
No. Eli Lilly describes retatrutide as investigational. In a 23 July 2026 release, Lilly said it plans to file with the FDA in the first quarter of 2027. The FDA also states that retatrutide cannot be used in compounding under federal law.
Is cagrilintide FDA-approved?
No. Cagrilintide is not approved on its own or as part of CagriSema. Novo Nordisk filed for CagriSema approval in December 2025, and a decision was expected in the fourth quarter of 2026. The FDA states cagrilintide cannot be used in compounding under federal law.
What is CagriSema?
CagriSema is Novo Nordisk's fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, given once weekly in trials. In the REDEFINE 1 trial, adults without diabetes lost 20.4% of body weight at 68 weeks, versus 3.0% on placebo. It contains semaglutide, not retatrutide.
How does cagrilintide differ from amylin?
Native amylin is a pancreatic hormone linked to satiety. Cagrilintide is an engineered, long-acting analogue developed for once-weekly dosing in clinical trials. The rat paper describes it as a co-agonist at amylin and calcitonin receptors. Our amylin guide covers the structural differences in more detail.
Why do pair-feeding experiments matter?
Pair-feeding shows whether weight loss goes beyond eating less. Control animals receive exactly what treated animals eat. If treated animals still lose more weight, appetite alone cannot explain it. In the rat study, this control suggested the combination's extra weight loss was not explained by food intake alone.
Is there a proven retatrutide and cagrilintide blend?
No. No published study has tested a premixed retatrutide and cagrilintide product in humans. The rat study's abstract describes co-administration, not a commercial blend. Any claim that a blend is "proven" in people goes beyond the published evidence reviewed on this page.
What does "unimolecular" mean for a multi-receptor agonist?
It means one molecule activates several receptors. Retatrutide is unimolecular because a single peptide reaches GLP-1, GIP and glucagon receptors. By contrast, the rat study combined two separate molecules to reach five receptors. The authors suggest future single molecules might cover all five.
How much weight loss did human trials of retatrutide report?
Results vary by population and trial length. In a phase 2 trial of 338 adults with obesity, the 12 mg group lost 24.2% at 48 weeks versus 2.1% on placebo. A 2026 Annals review reported −22.1% placebo-subtracted weight loss in adults without diabetes.
Where can I check the latest human trials for these compounds?
ClinicalTrials.gov lists registered trials, their phase and their recruitment status. PubMed indexes published results, and Drugs@FDA shows approval status. Company investor pages from Eli Lilly and Novo Nordisk often post topline results first. Always check the publication date, because this field changes quickly.
What is the difference between this rat study and a clinical trial?
A rat study tests biology in animals under controlled conditions over weeks. A clinical trial tests effect and safety in people, often for more than a year. Rat results can justify a trial, but they cannot predict human dose, tolerability or effect size.













